GE HEALTHCARE TECH.INC. Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/6/2026)
| Balance Sheet | Total Assets | 36,906,000,000.00 | ROE | 28.12 % |
| Balance Sheet | Total Equity | 10,379,000,000.00 | ROA | 5.65 % |
| Cashflow | Capital Expenditures | -482,000,000.00 | P/FCF | 12.04 |
| Cashflow | Free Cash Flow | 2,617,999,872.00 | – | – |
| Cashflow | Operating Cash Flow | 1,987,000,000.00 | P/CF | 10.17 |
| Income | Earnings per Share (diluted) | 0.30 | Div. Yield | 0.20 % |
| Income | Net Income | 2,084,000,000.00 | P/E | 15.05 |
| Income | Shares Outstanding | 454,000,000.00 | P/B | 3.04 |
| Income | Total Revenue | 20,625,000,000.00 | P/S | 1.53 |
Ratios calculated on: 10/14/2026
Company Description
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.gehealthcare.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more